NCT Number,Study Title,Study URL,Study Status,Conditions,Interventions,Sponsor,Collaborators,Study Type,,single_combination,Dose_finding,Design,other_design,more_than_one_drug,n_finding,dose_level,comment_finding,Dose_expansion,n_expansion,toxicity_stopping_rule,comment_expansion,phase2,n_phase2,comment_phase2,,,,,
NCT04086966,PSMA-PET/MRI for Radiation Treatment Planning in Patients With Locally Metastatic Prostate Cancer: A Pilot Study,https://clinicaltrials.gov/study/NCT04086966,COMPLETED,Metastatic Prostate Cancer,DRUG: [68Ga]PSMA-PET/MRI or PET/CT,University of Alabama at Birmingham,,INTERVENTIONAL,,Single ,No,,,,,,,No,,,,No,,,,,,,
NCT04299048,Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.,https://clinicaltrials.gov/study/NCT04299048,COMPLETED,Cachexia|Non-Small-Cell Lung Cancer|Pancreatic Cancer|Colorectal Cancer,DRUG: PF-06946860,Pfizer,,INTERVENTIONAL,,Single ,No,,,,,,,Yes,11,,,No,,,,,,,
NCT03502148,Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma,https://clinicaltrials.gov/study/NCT03502148,COMPLETED,Oral Squamous Cell Carcinoma,DRUG: PRV111 (Cisplatin Transmucosal System),Privo Technologies,National Cancer Institute (NCI),INTERVENTIONAL,,Single ,Yes,,,No,10,3,,Yes,21,No,,Yes,21,Same as dose-expansion (title is Phase 1/2),,,,,
NCT03817125,Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention,https://clinicaltrials.gov/study/NCT03817125,COMPLETED,Metastatic Melanoma,DRUG: Placebo for antibiotic|DRUG: Vancomycin pretreatment|DRUG: Nivolumab|DRUG: Matching Placebo for SER-401|DRUG: SER-401,Parker Institute for Cancer Immunotherapy,"Seres Therapeutics, Inc.",INTERVENTIONAL,,Combination,No,,,,,,,Yes,14,No,"placebo-controlled, triple-blinded",No,,,,,,,
NCT03916744,"A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer",https://clinicaltrials.gov/study/NCT03916744,COMPLETED,Breast Cancer,DRUG: Giredestrant|PROCEDURE: Surgery,"Genentech, Inc.",,INTERVENTIONAL,,Single ,Yes,Other,Parallel Assignment,No,75,3,,No,,,,No,,,,,,,
NCT03535727,"A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer",https://clinicaltrials.gov/study/NCT03535727,COMPLETED,"Adenocarcinoma|Pancreatic Neoplasms|Neoplasm, Glandular|Neoplasms|Neoplasms Pancreatic|Digestive System Neoplasm|Endocrine Gland Neoplasms|Digestive System Disease|Pancreatic Diseases|Endocrine System Diseases",DRUG: Nab-paclitaxel|DRUG: Gemcitabine|DRUG: Capecitabine|DRUG: Cisplatin|DRUG: Irinotecan|DRUG: Nab-paclitaxel|DRUG: Gemcitabine|DRUG: Capecitabine|DRUG: Cisplatin|DRUG: Irinotecan,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,INTERVENTIONAL,,Combination,Yes,3+3,,Yes,48,8,,Yes,48,Yes,,Yes,48,Same as dose-expansion,,,,,
NCT03387020,Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors,https://clinicaltrials.gov/study/NCT03387020,COMPLETED,"CNS Embryonal Tumor, Not Otherwise Specified|Malignant Glioma|Recurrent Atypical Teratoid/Rhabdoid Tumor|Recurrent Childhood Ependymoma|Recurrent Diffuse Intrinsic Pontine Glioma|Recurrent Medulloblastoma|Refractory Diffuse Intrinsic Pontine Glioma",DRUG: Everolimus|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study|DRUG: Ribociclib,Pediatric Brain Tumor Consortium,National Cancer Institute (NCI),INTERVENTIONAL,,Combination,Yes,,,Yes,22,6,,No,,,,No,,,,,,,
NCT03648073,[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma,https://clinicaltrials.gov/study/NCT03648073,COMPLETED,Hepatocellular Carcinoma,DRUG: [68Ga]DOTATATE-PET/MRI,University of Alabama at Birmingham,,INTERVENTIONAL,,Single ,No,,,,,,,No,,,,No,,,,,,,
NCT04247282,Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection,https://clinicaltrials.gov/study/NCT04247282,COMPLETED,Head and Neck Cancer|Head and Neck Neoplasms,DRUG: M7824|DRUG: N803|BIOLOGICAL: TriAd vaccine,National Cancer Institute (NCI),,INTERVENTIONAL,,Both,Yes,Other,Sequential Assignment,Yes,21,3,,No,,,,No,,,,,,,
NCT04081389,Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer,https://clinicaltrials.gov/study/NCT04081389,COMPLETED,Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Early-Stage Breast Carcinoma|Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma,DRUG: Celecoxib|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Doxorubicin Hydrochloride|DRUG: Paclitaxel|BIOLOGICAL: Recombinant Interferon Alfa-2b|DRUG: Rintatolimod,Roswell Park Cancer Institute,National Center for Advancing Translational Sciences (NCATS),INTERVENTIONAL,,Combination,Yes,,,Yes,9,,,Yes,9,No,,,,,,,,,
NCT03439462,Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT03439462,COMPLETED,Colorectal Cancer Metastatic,DRUG: nab-sirolimus,"Aadi Bioscience, Inc.",,INTERVENTIONAL,,Combination,,,,Yes,60,,,Yes,60,No,,,,,,,,,
NCT03439280,"A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)",https://clinicaltrials.gov/study/NCT03439280,COMPLETED,Relapsed/Refractory|Multiple Myeloma,DRUG: Mezagitamab|DRUG: Pomalidomide|DRUG: Dexamethasone,"Millennium Pharmaceuticals, Inc.",,INTERVENTIONAL,,Both,Yes,,,No,50,6,,Yes,50,No,,Yes,50,Same as dose-expansion,,,,,
NCT04607291,Health Service Intervention for the Improvement of Access and Adherence to Colorectal Cancer Screening,https://clinicaltrials.gov/study/NCT04607291,COMPLETED,Colorectal Carcinoma,OTHER: Community Health Service|OTHER: Survey Administration,Roswell Park Cancer Institute,National Cancer Institute (NCI),INTERVENTIONAL,,None,No,,,,,,,No,,,,No,,,,,,,
NCT04542291,Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition,https://clinicaltrials.gov/study/NCT04542291,COMPLETED,Pancreas Cancer|Pancreatic Cancer|Cancer of the Pancreas,DRUG: Dapagliflozin|DEVICE: BIOSENSE meters,Washington University School of Medicine,National Institutes of Health (NIH)|National Cancer Institute (NCI),INTERVENTIONAL,,Single ,Yes,,,No,15,2,,No,,,,No,,,,,,,
NCT04631029,"Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread",https://clinicaltrials.gov/study/NCT04631029,COMPLETED,Extensive Stage Lung Small Cell Carcinoma|Malignant Solid Neoplasm|Metastatic Malignant Neoplasm in the Brain,BIOLOGICAL: Atezolizumab|DRUG: Carboplatin|DRUG: Entinostat|DRUG: Etoposide,National Cancer Institute (NCI),,INTERVENTIONAL,,Combination,Yes,BOIN,,No,3,,,No,,,,No,,,,,,,
NCT03455829,"G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT03455829,COMPLETED,"Carcinoma, Non-Small-Cell Lung|Lung Cancer|Non-small Cell Lung Cancer",DRUG: G1T38|DRUG: Osimertinib,"G1 Therapeutics, Inc.",,INTERVENTIONAL,,Combination,Yes,Other,Parallel Assignment,,30,5,,Yes,114,No,was not conducted,No,,,,,,,
NCT03770260,Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment,https://clinicaltrials.gov/study/NCT03770260,COMPLETED,Recurrent Multiple Myeloma|Refractory Multiple Myeloma,DRUG: Ixazomib Citrate|DRUG: Pevonedistat,National Cancer Institute (NCI),,INTERVENTIONAL,,Combination,Yes,,,No,8,,,Yes,8,No,,,,,,,,,
NCT03749460,Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers,https://clinicaltrials.gov/study/NCT03749460,COMPLETED,Metastatic Malignant Neoplasm in the Bone|Metastatic Malignant Neoplasm in the Lung|Salivary Gland Carcinoma|Stage IV Major Salivary Gland Cancer AJCC v8|Stage IVA Major Salivary Gland Cancer AJCC v8|Stage IVB Major Salivary Gland Cancer AJCC v8|Stage IVC Major Salivary Gland Cancer AJCC v8,BIOLOGICAL: Nivolumab|BIOLOGICAL: Ipilimumab|RADIATION: Stereotactic Body Radiation Therapy,University of Washington,,INTERVENTIONAL,,Combination,No,,,,,,,Yes,20,No,,Yes,20,Same as dose-expansion,,,,,
NCT04185220,Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome,https://clinicaltrials.gov/study/NCT04185220,COMPLETED,Adult T-Cell Lymphoma/Leukemia|Sezary Syndrome|Mycosis Fungoides,DRUG: Recombinant human Interleukin-15 (rhIL-15)|BIOLOGICAL: Mogamulizumab,National Cancer Institute (NCI),,INTERVENTIONAL,,Combination,Yes,3+3,,No,6,2,,Yes,6,No,,No,,,,,,,
NCT03558139,Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy,https://clinicaltrials.gov/study/NCT03558139,COMPLETED,Ovarian Cancer,DRUG: Magrolimab|DRUG: Avelumab,Gilead Sciences,"Merck KGaA, Darmstadt, Germany",INTERVENTIONAL,,Combination,Yes,Other,Sequential Assignment,Yes,34,3,,Yes,34,No,,No,,,,,,,
NCT03315039,Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML),https://clinicaltrials.gov/study/NCT03315039,COMPLETED,"Leukemia, Myeloid, Acute",DRUG: Liposomal Annamycin,"Moleculin Biotech, Inc.",,INTERVENTIONAL,,Single ,Yes,Other,Sequential Assignment,No,7,2,,,,,,,,,,,,,
NCT04208958,Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer,https://clinicaltrials.gov/study/NCT04208958,COMPLETED,Metastatic Cancer|Melanoma|Gastric Cancer|Gastroesophageal Junction Adenocarcinoma|Colorectal Cancer,BIOLOGICAL: VE800|DRUG: Nivolumab|DRUG: Vancomycin Oral Capsule,"Vedanta Biosciences, Inc.",Bristol-Myers Squibb,INTERVENTIONAL,,Combination,Yes,,,Yes,56,,,Yes,56,,,Yes,56,,,,,,
NCT04075396,A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT04075396,COMPLETED,"Carcinoma, Non-Small-Cell Lung",DRUG: Lazertinib,"Janssen Research & Development, LLC",Yuhan Corporation,INTERVENTIONAL,,Single ,Yes,Other,Sequential Assignment,No,29,5,,Yes,29,,,Yes,29,Same as dose-expansion,,,,,
NCT03323658,Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer,https://clinicaltrials.gov/study/NCT03323658,COMPLETED,Breast Atypical Ductal Hyperplasia|Breast Atypical Lobular Hyperplasia|Breast Ductal Carcinoma In Situ|Breast Lobular Carcinoma In Situ|Invasive Breast Carcinoma,DRUG: Bexarotene|OTHER: Questionnaire Administration,National Cancer Institute (NCI),,INTERVENTIONAL,,Single ,Yes,Other,Sequential Assignment,No,24,3,,No,,,,No,,,,,,,
NCT04179396,Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP),https://clinicaltrials.gov/study/NCT04179396,COMPLETED,Metastatic Castration Resistant Prostate Cancer,DRUG: Rucaparib|DRUG: Enzalutamide|DRUG: Abiraterone,pharmaand GmbH,,INTERVENTIONAL,,Combination,No,,,,,,,Yes,26,No,,No,,,,,,,
NCT03384316,Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer,https://clinicaltrials.gov/study/NCT03384316,COMPLETED,Neoplasms|Prostate Cancer|Lung Cancer|Breast Cancer|Colon Cancer,BIOLOGICAL: ETBX-051; adenoviral brachyury vaccine|BIOLOGICAL: ETBX-061; adenoviral Mucin-1 (MUC1) vaccine|BIOLOGICAL: ETBX-011; adenoviral Carcinoembryonic antigen (CEA) vaccine,National Cancer Institute (NCI),,INTERVENTIONAL,,Combination,Yes,Other,Sequential Assignment,Yes,11,2,,No,,,,No,,,,,,,
NCT03443635,Cooking for Health Optimization With Patients,https://clinicaltrials.gov/study/NCT03443635,COMPLETED,Cardiovascular Diseases|Cardiovascular Risk Factor|Nutrition Disorders|Diabetes|Hypertension|Cancer|Depression|Obesity|Physical Activity,BEHAVIORAL: Treatment,Tulane University,,INTERVENTIONAL,,None,No,,,,,2,,No,,,,No,,,,,,,
NCT04614363,68 Ga-PSMA for High Risk Prostate Cancer,https://clinicaltrials.gov/study/NCT04614363,COMPLETED,Prostate Cancer|High Risk,DRUG: 68Ga-PSMA,The Methodist Hospital Research Institute,,INTERVENTIONAL,,Single ,No,,,,,,,No,,,,No,,,,,,,
NCT05093322,"A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors",https://clinicaltrials.gov/study/NCT05093322,COMPLETED,Solid Tumor|Lymphoma|Osteosarcoma|Ewing Sarcoma|Rhabdomyosarcoma|Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS),DRUG: Surufatinib in combination with Gemcitabine,Hutchmed,,INTERVENTIONAL,,Combination,Yes,Other,Sequential Assignment,No,13,4,,Yes,13,,,Yes,13,Same as dose-expansion,,,,,
NCT03101358,Study of Topical SOR007 Ointment for Cutaneous Metastases,https://clinicaltrials.gov/study/NCT03101358,COMPLETED,Cutaneous Metastasis,DRUG: SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment,"NanOlogy, LLC","US Biotest, Inc.",INTERVENTIONAL,,Single ,Yes,3+3 and other,Sequential Assignment,No,23,3,,Yes,23,Yes,,Yes,,Same as dose-expansion,,,,,
NCT03905135,Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies,https://clinicaltrials.gov/study/NCT03905135,COMPLETED,Peripheral T-cell Lymphoma NOS|Mycosis Fungoides|Sezary Syndrome|Anaplastic Large Cell Lymphoma,DRUG: rhIL-15|DRUG: rhIL-15|BIOLOGICAL: Avelumab,National Cancer Institute (NCI),,INTERVENTIONAL,,Combination,Yes,3+3 and other,Sequential Assignment,No,8,4,,Yes,8,No,,No,,,,,,,
NCT04052334,Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma,https://clinicaltrials.gov/study/NCT04052334,COMPLETED,Sarcoma,DRUG: TIL|DRUG: Interleukin-2|DRUG: Fludarabine|DRUG: Cyclophosphamide,H. Lee Moffitt Cancer Center and Research Institute,"Iovance Biotherapeutics, Inc.|The V Foundation for Cancer Research|National Cancer Institute (NCI)",INTERVENTIONAL,,,,,,,,,,,,,,,,,,,,,
NCT03949517,68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy,https://clinicaltrials.gov/study/NCT03949517,COMPLETED,Prostate Cancer,DRUG: 68-Ga RM2|DRUG: 68-Ga PSMA11|DEVICE: Investigational software and coils in PET/MR Scan|PROCEDURE: PET/MRI,Andrei Iagaru,General Electric,INTERVENTIONAL,,Combination,,,,,,,,,,,,,,,,,,,
NCT04079296,"A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)",https://clinicaltrials.gov/study/NCT04079296,COMPLETED,Acute Myeloid Leukemia (AML)|Myelodysplastic Syndrome,BIOLOGICAL: ASP7517,"Astellas Pharma Global Development, Inc.",,INTERVENTIONAL,,Single ,Yes,Other,Sequential Assignment,No,43,3,,Yes,43,No,,Yes,43,Same as dose-expansion,,,,,
NCT03568539,IBI308 in Subjects With Advanced/Metastatic Solid Malignancies,https://clinicaltrials.gov/study/NCT03568539,COMPLETED,Advanced/Metastatic Solid Malignancies,DRUG: IBI308,Innovent Biologics (Suzhou) Co. Ltd.,,INTERVENTIONAL,,Single ,No,,,,,,,Yes,39,No,,No,,,,,,,
NCT03565367,Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors,https://clinicaltrials.gov/study/NCT03565367,COMPLETED,Malignant Central Nervous System Neoplasm|Metastatic Malignant Neoplasm in the Central Nervous System,OTHER: Gadolinium|DRUG: Hyperpolarized Carbon C 13 Pyruvate|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Magnetic Resonance Spectroscopic Imaging,Daniel M. Spielman,National Institutes of Health (NIH)|National Cancer Institute (NCI),INTERVENTIONAL,,,,,,,,,,,,,,,,,,,,,
NCT03907969,A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.,https://clinicaltrials.gov/study/NCT03907969,COMPLETED,Advanced Malignancies,DRUG: AZD7648|DRUG: PLD,AstraZeneca,Parexel,INTERVENTIONAL,,Both,Yes,Other,Sequential Assignment,,,,,,,,,,,,,,,,
NCT03704467,Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer,https://clinicaltrials.gov/study/NCT03704467,COMPLETED,Ovarian Cancer,DRUG: M6620|DRUG: Avelumab|DRUG: Carboplatin,"EMD Serono Research & Development Institute, Inc.","Merck KGaA, Darmstadt, Germany",INTERVENTIONAL,,Combination,,,,,,3,,,,,,Yes,,not conducted,,,,,
NCT03194867,Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients,https://clinicaltrials.gov/study/NCT03194867,COMPLETED,Plasma Cell Myeloma,DRUG: Isatuximab SAR650984|DRUG: Cemiplimab REGN2810,Sanofi,,INTERVENTIONAL,,Combination,,,,,,,,Yes,,,,,,,,,,,
NCT03256344,Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases,https://clinicaltrials.gov/study/NCT03256344,COMPLETED,Metastatic Triple Negative Breast Cancer|Metastatic Colorectal Cancer,BIOLOGICAL: Talimogene Laherparepvec|BIOLOGICAL: Atezolizumab,Amgen,Roche-Genentech,INTERVENTIONAL,,Combination,,,,,,,,,,,,,,,,,,,
NCT03770689,Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer,https://clinicaltrials.gov/study/NCT03770689,COMPLETED,Locally Advanced Rectal Cancer,DRUG: Peposertib 50 mg|DRUG: Peposertib 100 mg|DRUG: Peposertib 150 mg|DRUG: Peposertib 250 mg|DRUG: Capecitabine|RADIATION: Radiotherapy (RT),"EMD Serono Research & Development Institute, Inc.","Merck KGaA, Darmstadt, Germany",INTERVENTIONAL,,Combination,Yes,,,No,19,4,,Yes,19,,,Yes,19,total enrollment N=19,,,,,
NCT04630769,FT516 and IL2 With Enoblituzumab for Ovarian Cancer,https://clinicaltrials.gov/study/NCT04630769,COMPLETED,Ovarian Cancer|Fallopian Tube Adenocarcinoma|Primary Peritoneal Cavity Cancer,DRUG: IP FT516|DRUG: Enoblituzumab|DRUG: IL-2,"Masonic Cancer Center, University of Minnesota",National Cancer Institute (NCI),INTERVENTIONAL,,Combination,,,,,,,,,,,,,,,,,,,
NCT03615404,"Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma",https://clinicaltrials.gov/study/NCT03615404,COMPLETED,"Glioblastoma|Malignant Glioma|Medulloblastoma Recurrent|Pediatric Glioblastoma Multiforme|Pediatric Brain Tumor, Recurrent|Pediatric Brain Tumor",BIOLOGICAL: CMV-DCs with GM-CSF|BIOLOGICAL: Td (tetanus toxoid),Gary Archer Ph.D.,,INTERVENTIONAL,,,,,,,,,,,,,,,,,,,,,
NCT03693612,GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT03693612,COMPLETED,Neoplasms,DRUG: feladilimab|DRUG: Tremelimumab|DRUG: Docetaxel|DRUG: Paclitaxel|DRUG: Cetuximab,GlaxoSmithKline,MedImmune LLC,INTERVENTIONAL,,Combination,Yes,Other,Parallel Assignment,,,,,,,,,,,,,,,,
NCT03918499,"IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer",https://clinicaltrials.gov/study/NCT03918499,COMPLETED,Clinical Stage IV Gastric Cancer AJCC v8|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Gastric Cancer AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVB Gastric Cancer AJCC v8|Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Metastatic Gastric Adenocarcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Pathologic Stage IV Gastric Cancer AJCC v8|Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8|Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Recurrent Gastric Adenocarcinoma|Recurrent Gastroesophageal Junction Adenocarcinoma,DRUG: Cyclophosphamide|BIOLOGICAL: Cytokine-based Biologic Agent IRX-2|BIOLOGICAL: Pembrolizumab,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL,,Combination,,,,,,,,,,,,,,,,,,,
NCT03531918,"Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm",https://clinicaltrials.gov/study/NCT03531918,COMPLETED,Acute Myeloid Leukemia,DRUG: Cladribine|DRUG: Cytarabine|DRUG: Gemtuzumab Ozogamicin|BIOLOGICAL: Recombinant Granulocyte Colony-Stimulating Factor|OTHER: Laboratory Biomarker Analysis|DRUG: Mitoxantrone Hydrochloride,Fred Hutchinson Cancer Center,Pfizer,INTERVENTIONAL,,Combination,Yes,,,No,66,,,Yes,66,Yes,,Yes,66,Same as dose-expansion,,,,,
NCT04045613,Derazantinib and Atezolizumab in Patients With Urothelial Cancer,https://clinicaltrials.gov/study/NCT04045613,COMPLETED,Urothelial Carcinoma,DRUG: Derazantinib 300 mg once daily monotherapy|DRUG: Derazantinib 200 mg once daily + atezolizumab 1200 mg|DRUG: Derazantinib 300 mg once daily+ atezolizumab 1200 mg|DRUG: Derazantinib 200 mg twice daily + atezolizumab 1200 mg|DRUG: Derazantinib 300 mg once daily monotherapy (QD)|DRUG: Derazantinib 300 mg once daily + atezolizumab 1200 mg|DRUG: Derazantinib 200 mg twice daily monotherapy,Basilea Pharmaceutica,,INTERVENTIONAL,,Combination,No,,,,,,,Yes,95,Yes,,Yes,95,Same as dose-expansion,,,,,
NCT03789175,Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome,https://clinicaltrials.gov/study/NCT03789175,COMPLETED,Cancer|Skin Fibroblasts|Muscle Weakness,DIETARY_SUPPLEMENT: Nicotinamide Riboside (NR),"National Heart, Lung, and Blood Institute (NHLBI)",,INTERVENTIONAL,,Single ,No,,,,,,,No,,,,No,,,,,,,
NCT03847519,Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03847519,COMPLETED,"Lung Cancer, Non-Small Cell|Metastatic Squamous Cell Carcinoma|Metastatic Non-Squamous Cell Carcinoma",DRUG: ADXS-503|DRUG: Pembrolizumab,"Advaxis, Inc.",,INTERVENTIONAL,,Both,Yes,3+3,,No,24,2,,Yes,24,No,,Yes,24,Same as dose-expansion,,,,,
NCT03566199,MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma,https://clinicaltrials.gov/study/NCT03566199,COMPLETED,Diffuse Intrinsic Pontine Glioma,DRUG: Panobinostat Nanoparticle Formulation MTX110|DRUG: Convection-Enhanced Delivery (CED),"Sabine Mueller, MD, PhD",Midatech Pharma US Inc.|Pacific Pediatric Neuro-Oncology Consortium,INTERVENTIONAL,,Single ,No,,,,,,,Yes,7,Yes,,Yes,7,Same as dose-expansion,,,,,
NCT03322384,"UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma",https://clinicaltrials.gov/study/NCT03322384,COMPLETED,Advanced Solid Tumors|Lymphoma,DRUG: epacadostat|DRUG: SD-101|RADIATION: Radiotherapy,"University of California, Davis",,INTERVENTIONAL,,Combination,Yes,3+3,,No,20,3,,Yes,20,Yes,,Yes,20,Same as dose-expansion,,,,,
NCT03433781,A Phase Ib Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations,https://clinicaltrials.gov/study/NCT03433781,COMPLETED,Myelodysplastic Syndromes,DRUG: Vitamin C,NYU Langone Health,Perlmutter Cancer Center,INTERVENTIONAL,,Single ,Yes,3+3,,No,,3,,Yes,,,deferred to new clinical trial,Yes,,deferred to new clinical trial,,,,,
NCT03730012,A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML),https://clinicaltrials.gov/study/NCT03730012,COMPLETED,Acute Myeloid Leukemia (AML)|Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation,DRUG: gilteritinib|DRUG: atezolizumab,"Astellas Pharma Global Development, Inc.",,INTERVENTIONAL,,Combination,Yes,3+3,,Yes,11,2,,Yes,11,Yes,,Yes,11,Same as dose-expansion,,,,,
NCT03348514,"Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors",https://clinicaltrials.gov/study/NCT03348514,COMPLETED,Advanced Solid Tumors,DRUG: CPX-POM - 30 mg/m^2|DRUG: CPX-POM - 60 mg/m^2|DRUG: CPX-POM - 120 mg/m^2|DRUG: CPX-POM - 240 mg/m^2|DRUG: CPX-POM - 360 mg/m^2|DRUG: CPX-POM - 600 mg/m^2|DRUG: CPX-POM - 900 mg/m^2|DRUG: CPX-POM - 1200 mg/m^2,CicloMed LLC,Cmed Clinical Services,INTERVENTIONAL,,Single ,Yes,3+3,,No,19,8,,No,,,,No,,,,,,,
NCT03486314,A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT03486314,COMPLETED,Advanced Solid Neoplasm,DRUG: Pevonedistat|DRUG: Rifampin|DRUG: Docetaxel|DRUG: Carboplatin|DRUG: Paclitaxel,"Millennium Pharmaceuticals, Inc.",,INTERVENTIONAL,,Combination,,,,,,,,,,,,,,,,,,,
NCT04030195,Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL,https://clinicaltrials.gov/study/NCT04030195,COMPLETED,"Non-Hodgkin's Lymphoma, Relapsed|Chronic Lymphoid Leukemia in Relapse|Non-Hodgkin's Lymphoma Refractory|Chronic Lymphocytic Leukemia|Lymphoma, Non-Hodgkin|Leukemia, Lymphocytic, Chronic|B-cell Chronic Lymphocytic Leukemia|B-cell Non Hodgkin Lymphoma|Small Lymphocytic Lymphoma",GENETIC: PBCAR20A|DRUG: Fludarabine|DRUG: Cyclophosphamide,"Precision BioSciences, Inc.",,INTERVENTIONAL,,Combination,Yes,3+3,,No,18,3,,Yes,0,,did not proceed,Yes,0,Same as dose-expansion,,,,,
NCT03447314,Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT03447314,COMPLETED,Neoplasms,DRUG: GSK1795091|DRUG: GSK3174998|DRUG: GSK3359609|DRUG: Pembrolizumab,GlaxoSmithKline,Iqvia Pty Ltd,INTERVENTIONAL,,Combination,Yes,,,No,54,10,,Yes,,,did not proceed,No,,,,,,,
NCT03489369,Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas,https://clinicaltrials.gov/study/NCT03489369,COMPLETED,Metastatic Cancer|Solid Tumor|Lymphoma,DRUG: Sym022,Symphogen A/S,,INTERVENTIONAL,,Single ,Yes,3+3,,No,15,4,,No,,,,No,,,,,,,
NCT03941769,2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II,https://clinicaltrials.gov/study/NCT03941769,COMPLETED,"Acute Myeloid Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Cord Blood Transplant Recipient|Myelodysplastic Syndrome|Myeloproliferative Neoplasm",BIOLOGICAL: Recombinant Interleukin-7,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL,,,,,,,,,,,,,,,,,,,,,
NCT04116710,A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors,https://clinicaltrials.gov/study/NCT04116710,COMPLETED,Advanced Solid Tumor,BIOLOGICAL: HS-110 (viagenpumatucel-L)|BIOLOGICAL: HS-130,Heat Biologics,,INTERVENTIONAL,,Combination,Yes,3+3,,Yes,16,7,,No,,,,No,,,,,,,
NCT03665285,A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors,https://clinicaltrials.gov/study/NCT03665285,COMPLETED,Advanced or Metastatic Solid Tumors|Lung Cancer|Breast Cancer|Head and Neck Squamous Cell Carcinoma|Endometrial Cancer|Melanoma|CRC|Urothelial Carcinoma|Cholangiocarcinoma,DRUG: NC318,"NextCure, Inc.",,INTERVENTIONAL,,Single ,Yes,3+3,,Yes,109,7,,Yes,109,No,total enrollment N=109,,,,,,,,
NCT03701295,"Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement",https://clinicaltrials.gov/study/NCT03701295,COMPLETED,Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL|Leukemia Cutis|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia,DRUG: Azacitidine|DRUG: Pinometostat,National Cancer Institute (NCI),,INTERVENTIONAL,,Combination,Yes,3+3,,Yes,1,2,,No,,,skipped to Phase 2,Yes,1,total enrollment N=1,,,,,
NCT05045638,Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants,https://clinicaltrials.gov/study/NCT05045638,COMPLETED,Healthy Participants,DRUG: Rosuvastatin|DRUG: Sotorasib,Amgen,,INTERVENTIONAL,,Single ,No,,,,,,,No,,,,No,,,,,,,
NCT03665155,"First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody",https://clinicaltrials.gov/study/NCT03665155,COMPLETED,Multiple Myeloma,DRUG: 89Zr-daratumumab|DEVICE: PET/CT scans|OTHER: Blood draws,Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL,,Combination,No,,,,,,,No,,,,No,,,,,,,
NCT03877055,A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma,https://clinicaltrials.gov/study/NCT03877055,COMPLETED,Mantle Cell Lymphoma (MCL),DRUG: Copanlisib|DRUG: Ibrutinib,Memorial Sloan Kettering Cancer Center,Bayer,INTERVENTIONAL,,Combination,Yes,3+3,,Yes,8,3,,Yes,8,Yes,,Yes,8,Same as dose-expansion,,,,,
NCT04524455,Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL,https://clinicaltrials.gov/study/NCT04524455,COMPLETED,Acute Lymphoblastic Leukemia,DRUG: Blinatumomab|DRUG: AMG 404|DRUG: Dexamethasone Premedication,Amgen,,INTERVENTIONAL,,Combination,Yes,,,Yes,17,,,Yes,17,No,,Yes,17,Same as dose-expansion,,,,,
NCT03544281,"To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)",https://clinicaltrials.gov/study/NCT03544281,COMPLETED,Multiple Myeloma,DRUG: Belantamab mafodotin|DRUG: Lenalidomide|DRUG: Dexamethasone|DRUG: Bortezomib,GlaxoSmithKline,Iqvia Pty Ltd,INTERVENTIONAL,,Combination,Yes,,,Yes,153,3,,Yes,153,Yes,,Yes,153,Same as dose-expansion,,,,,
NCT03131999,LAM Pilot Study With Imatinib Mesylate,https://clinicaltrials.gov/study/NCT03131999,COMPLETED,Lymphangioleiomyomatosis,DRUG: Imatinib Mesylate 400Mg Capsule|DRUG: Placebo - Capsule,Medical University of South Carolina,Columbia University,INTERVENTIONAL,,Single ,No,,,,,,,No,,,,No,,,,,,,
NCT03329937,Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer,https://clinicaltrials.gov/study/NCT03329937,COMPLETED,"Neoplasms, Breast",DRUG: Niraparib,"Tesaro, Inc.",,INTERVENTIONAL,,Single ,No,,,,,,,No,,,,No,,,,,,,
NCT04319159,Study to Evaluate the Safety of BF-200 ALA (Ameluz¬Æ) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK),https://clinicaltrials.gov/study/NCT04319159,COMPLETED,Actinic Keratoses,COMBINATION_PRODUCT: BF-200 ALA and red light LED lamp,Biofrontera Bioscience GmbH,,INTERVENTIONAL,,Single ,No,,,,,,,No,,,,No,,,,,,,
NCT03892642,Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer,https://clinicaltrials.gov/study/NCT03892642,COMPLETED,Bladder Cancer,DRUG: Avelumab|BIOLOGICAL: BCG,University of Oklahoma,EMD Serono,INTERVENTIONAL,,Combination,Yes,3+3,,Yes,18,3,,Yes,18,No,,Yes,18,Same as dose-expansion,,,,,
NCT03391232,PolyPEPI1018 Vaccine and CDx for the Treatment of Metastatic Colorectal Cancer (OBERTO),https://clinicaltrials.gov/study/NCT03391232,COMPLETED,Colorectal Cancer,BIOLOGICAL: PolyPEPI1018 CRC Vaccine,Treos Bio Zrt,Mayo Clinic|University of Pisa|Laboratory Corporation of America|PPD|ImmunXperts SA,INTERVENTIONAL,,Single ,No,,,,,,,Yes,11,Yes,,Yes,11,Same as dose-expansion,,,,,
NCT04148937,A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer,https://clinicaltrials.gov/study/NCT04148937,COMPLETED,Advanced Cancer,DRUG: LY3475070|DRUG: Pembrolizumab,Eli Lilly and Company,Merck Sharp & Dohme LLC,INTERVENTIONAL,,Both,Yes,Other,Parallel Assignment,Yes,52,2,,Yes,52,No,,No,,,,,,,
NCT03531632,MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT03531632,COMPLETED,Colorectal Cancer Metastatic,BIOLOGICAL: MGD007 + MGA012,MacroGenics,,INTERVENTIONAL,,Combination,Yes,,,Yes,,3,,No,,,,Yes,,no info ,,,,,
NCT03490032,68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa),https://clinicaltrials.gov/study/NCT03490032,COMPLETED,Prostate Cancer Metastatic,DRUG: [68Ga]-PSMA-R2,Advanced Accelerator Applications,,INTERVENTIONAL,,Single ,No,,,,,,,Yes,30,No,,Yes,30,Same as dose-expansion,,,,,
NCT04074343,TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma,https://clinicaltrials.gov/study/NCT04074343,COMPLETED,Gastric Adenocarcinoma|GastroEsophageal Cancer,DRUG: TAS-102|DRUG: Irinotecan,"University of California, Irvine","Taiho Pharmaceutical Co., Ltd.",INTERVENTIONAL,,Combination,Yes,,,Yes,20,,,Yes,20,No,,,,,,,,,
NCT03489343,Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas,https://clinicaltrials.gov/study/NCT03489343,COMPLETED,Metastatic Cancer|Solid Tumor|Lymphoma,DRUG: Sym023,Symphogen A/S,,INTERVENTIONAL,,Single ,Yes,,,No,,7,,No,,,,No,,,,,,,
NCT04534738,The Effect of a Mediterranean Diet Intervention on Cancer-related Fatigue and Mitochondrial Function During Chemotherapy,https://clinicaltrials.gov/study/NCT04534738,COMPLETED,Cancer,BEHAVIORAL: Mediterranean Diet,University of Rochester,,INTERVENTIONAL,,None,No,,,,,,,No,,,,No,,,,,,,
NCT04629443,Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia,https://clinicaltrials.gov/study/NCT04629443,COMPLETED,Acute Myeloid Leukaemia,DRUG: S 64315 (also referred as MIK665) and azacitidine,Institut de Recherches Internationales Servier,"ADIR, a Servier Group company",INTERVENTIONAL,,Combination,Yes,,,No,,,,No,,,,No,,,,,,,
NCT03359850,Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients,https://clinicaltrials.gov/study/NCT03359850,COMPLETED,Ovarian Neoplasms|Neoplasms|Solid Tumor|Hepatic Impairment,DRUG: Niraparib,"Tesaro, Inc.",,INTERVENTIONAL,,Single ,Yes,,,No,17,3,,Yes,17,No,,No,,,,,,,
NCT04551950,Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046),https://clinicaltrials.gov/study/NCT04551950,COMPLETED,Cervical Cancer,DRUG: M7824|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Bevacizumab|DRUG: Cisplatin|RADIATION: Radiotherapy,"EMD Serono Research & Development Institute, Inc.","Merck KGaA, Darmstadt, Germany",INTERVENTIONAL,,Combination,No,,,,,,,,,,,,,,,,,,
NCT02834052,Pembrolizumab + Poly-ICLC in MRP Colon Cancer,https://clinicaltrials.gov/study/NCT02834052,COMPLETED,Metastatic Colon Cancer|Solid Tumor,DRUG: pembrolizumab|DRUG: Poly-ICLC,Asha Nayak,"Oncovir, Inc.|Merck Sharp & Dohme LLC",INTERVENTIONAL,,Combination,Yes,3+3,,Yes,42,3,,Yes,42,No,,Yes,42,Same as dose-expansion,,,,,
NCT03300570,Dolcanatide in Preventing Colorectal Cancer in Healthy Volunteers,https://clinicaltrials.gov/study/NCT03300570,COMPLETED,Colorectal Carcinoma,DRUG: Dolcanatide|OTHER: Laboratory Biomarker Analysis|OTHER: Placebo Administration|OTHER: Questionnaire Administration,National Cancer Institute (NCI),,INTERVENTIONAL,,Single ,Yes,,,No,27,,,No,,,,No,,,,,,,
NCT03770000,Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma,https://clinicaltrials.gov/study/NCT03770000,COMPLETED,T Cell Lymphoma,DRUG: Tenalisib|DRUG: Romidepsin,Rhizen Pharmaceuticals SA,,INTERVENTIONAL,,Combination,Yes,3+3,,No,33,3,,Yes,33,Yes,,Yes,33,Same as dose-expansion,,,,,
NCT03636256,Evaluation of NanoDoce¬Æ in Participants With Urothelial Carcinoma,https://clinicaltrials.gov/study/NCT03636256,COMPLETED,Bladder Cancer|Urothelial Carcinoma|Urinary Bladder Neoplasm|Urinary Bladder Cancer|Urogenital Neoplasms|Urologic Neoplasms|Urologic Cancer|Malignant Tumor of the Urinary Bladder|Cancer of the Bladder,DRUG: NanoDoce (direct injection)|DRUG: NanoDoce (intravesical instillation) - Visit 2 Instillation|OTHER: Institutional Standard of Care|DRUG: NanoDoce (intravesical instillation) - Induction and Maintenance Instillations,"NanOlogy, LLC","US Biotest, Inc.",INTERVENTIONAL,,Single ,Yes,3+3,,No,36,4,,No,,,,Yes,36,total enrollment N=36,,,,,
NCT03704688,Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03704688,COMPLETED,Non Small Cell Lung Cancer|KRAS Gene Mutation,DRUG: Trametinib 0.5 mg|DRUG: Trametinib 1 MG|DRUG: Trametinib 1.5 MG|DRUG: Trametinib 2 mg|DRUG: Ponatinib 15 MG|DRUG: Ponatinib 30 MG,Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL,,Combination,Yes,3+3,Parallel Assignment,Yes,12,5,,No,,,,Yes,12,total enrollment N=12,,,,,
NCT03835533,Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations,https://clinicaltrials.gov/study/NCT03835533,COMPLETED,Metastatic Castration-resistant Prostate Cancer,"DRUG: NKTR-214 (Cohort A)|DRUG: Nivolumab (Cohort A, B and C)|RADIATION: Stereotactic body radiation therapy (SBRT) (Cohort B)|DRUG: CDX-301 (Cohort B and C)|DRUG: Poly-ICLC (Cohort B)|DRUG: INO-5151 (Cohort C)|DEVICE: Cellectra 2000",Parker Institute for Cancer Immunotherapy,"Bristol-Myers Squibb|Celldex Therapeutics|Cancer Research Institute, New York City|Inovio Pharmaceuticals|Oncovir, Inc.",INTERVENTIONAL,,Combination,No,,,,,,,No,,,,No,,,,,,,
NCT03840915,M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT03840915,COMPLETED,"Carcinoma, Non-Small-Cell Lung",DRUG: Cisplatin|DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Nab-paclitaxel|DRUG: Gemcitabine|DRUG: Docetaxel|DRUG: M7824|DRUG: Carboplatin|DRUG: Carboplatin|DRUG: Bintrafusp alfa|DRUG: Paclitaxel,"EMD Serono Research & Development Institute, Inc.","Merck KGaA, Darmstadt, Germany",INTERVENTIONAL,,Combination,No,,,,,,,Yes,70,No,,Yes,70,Same as dose-expansion,,,,,
NCT03394885,Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer,https://clinicaltrials.gov/study/NCT03394885,COMPLETED,Ovarian Cancer|Ovarian Neoplasms,DRUG: Atezolizumab|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Bevacizumab,Duke University,"Johns Hopkins University|Genentech, Inc.",INTERVENTIONAL,,Combination,No,,,,,,,Yes,18,Yes,,Yes,18,Same as dose-expansion,,,,,
NCT03291288,Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics),https://clinicaltrials.gov/study/NCT03291288,COMPLETED,Drug Interaction Potential,DRUG: Tolbutamide|DRUG: Midazolam|DRUG: Pexidartinib,Daiichi Sankyo,,INTERVENTIONAL,,Single ,No,,,,,,,Yes,32,No,,No,,,,,,,
NCT03853707,"Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer",https://clinicaltrials.gov/study/NCT03853707,COMPLETED,Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8,DRUG: Atezolizumab|DRUG: Capecitabine|DRUG: Carboplatin|DRUG: Ipatasertib|DRUG: Paclitaxel|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL,,Combination,Yes,3+3,,Yes,28,,,Yes,28,,,Yes,28,Same as dose-expansion,,,,,
NCT03989115,Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC,https://clinicaltrials.gov/study/NCT03989115,COMPLETED,Solid Tumor,DRUG: RMC-4630|DRUG: Cobimetinib|DRUG: Drug: Osimertinib,"Revolution Medicines, Inc.",Sanofi,INTERVENTIONAL,,Combination,Yes,CRM,,Yes,117,2,,Yes,,No,,Yes,,Same as dose-expansion,,,,,
NCT03611556,MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.,https://clinicaltrials.gov/study/NCT03611556,COMPLETED,Carcinoma|Metastatic Pancreatic Adenocarcinoma,DRUG: Oleclumab|DRUG: Durvalumab|DRUG: Gemcitabine|DRUG: Nab-paclitaxel|DRUG: Oxaliplatin|DRUG: Folinic acid|DRUG: 5-FU,MedImmune LLC,,INTERVENTIONAL,,Combination,Yes,,,No,213,3,,Yes,213,No,,Yes,213,Same as dose-expansion,,,,,
NCT03548207,"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma",https://clinicaltrials.gov/study/NCT03548207,COMPLETED,Multiple Myeloma,BIOLOGICAL: JNJ-68284528,"Janssen Research & Development, LLC",,INTERVENTIONAL,,Single ,Yes,,,No,126,3,,No,,,,Yes,126,total enrollment N=126,,,,,
NCT03773107,LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma,https://clinicaltrials.gov/study/NCT03773107,COMPLETED,Multiple Myeloma,DRUG: Carfilzomib|DRUG: Ruxolitinib|DRUG: Dexamethasone,Wake Forest University Health Sciences,Incyte Corporation|Multiple Myeloma Research Consortium|Amgen,INTERVENTIONAL,,Combination,Yes,3+3,,No,12,3,,No,,,,Yes,12,total enrollment N=12,,,,,
NCT03958656,T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma,https://clinicaltrials.gov/study/NCT03958656,COMPLETED,"Myeloma-Multiple|Myeloma, Plasma-Cell",DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Rimiducid|BIOLOGICAL: Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells,National Cancer Institute (NCI),,INTERVENTIONAL,,Single ,Yes,3+3,,No,13,5,,No,,,,No,,,,,,,
NCT04177693,Pharmacokinetics and Hepatic Safety of EGCG,https://clinicaltrials.gov/study/NCT04177693,COMPLETED,Uterine Fibroids,DIETARY_SUPPLEMENT: Epigallocatechin gallate (EGCG)|DRUG: Clomiphene Citrate|DRUG: Letrozole,Yale University,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Illinois at Chicago|Johns Hopkins University|University of Chicago,INTERVENTIONAL,,Both,No,,,,,,,No,,,,No,,,,,,,
NCT03258593,Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG),https://clinicaltrials.gov/study/NCT03258593,COMPLETED,Urinary Bladder Neoplasms,DRUG: Durvalumab|DRUG: Vicineum|DRUG: Acetaminophen|DRUG: Antihistamine|PROCEDURE: Bladder Biopsy|PROCEDURE: TURBT|PROCEDURE: Cystoscopy|DIAGNOSTIC_TEST: Urine cytology|DIAGNOSTIC_TEST: Electrocardiogram|DIAGNOSTIC_TEST: CT|DIAGNOSTIC_TEST: MRI,National Cancer Institute (NCI),,INTERVENTIONAL,,Combination,Yes,3+3,,Yes,15,2,,Yes,15,No,,No,,,,,,,
NCT04803305,Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia,https://clinicaltrials.gov/study/NCT04803305,COMPLETED,Non-small Cell Lung Cancer|Pancreatic Cancer|Colorectal Cancer|Prostate Cancer|Breast Cancer|Ovarian Cancer|Loss of Appetite|Fatigue|Cachexia|Anorexia,DRUG: PF-06946860|DRUG: Placebo for PF-06946860,Pfizer,,INTERVENTIONAL,,Single ,No,,,,,,,No,,,,No,,,,,,,
NCT04685811,Evaluation of PSMA Antagonist Produced by Two Different Methods,https://clinicaltrials.gov/study/NCT04685811,COMPLETED,Metastatic Prostate Adenocarcinoma,DRUG: 68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron,Weill Medical College of Cornell University,National Institutes of Health (NIH)|National Cancer Institute (NCI),INTERVENTIONAL,,Single ,No,,,,,,,No,,,,No,,,,,,,
NCT03430011,Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma,https://clinicaltrials.gov/study/NCT03430011,COMPLETED,Multiple Myeloma,BIOLOGICAL: JCARH125|BIOLOGICAL: JCARH125 + anakinra,"Juno Therapeutics, a Subsidiary of Celgene",,INTERVENTIONAL,,Both,Yes,mTPI,,No,165,5,,Yes,165,No,,Yes,165,Same as dose-expansion,,,,,
NCT03346161,Optimizing Decision Making About Breast Reconstruction After Mastectomy: A Patient-Centered Approach,https://clinicaltrials.gov/study/NCT03346161,COMPLETED,Breast Cancer,"OTHER: Usual care American Society of Plastic Surgeons booklet ""Breast Reconstruction""|OTHER: Decision tool|OTHER: Usual Care Group - Outcome Measures|OTHER: Decision Group - Outcome Measures|OTHER: Demographic and Background Questions",Washington University School of Medicine,,INTERVENTIONAL,,None,No,,,,,,,No,,,,No,,,,,,,
NCT04574583,"Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta ""Trap""/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)",https://clinicaltrials.gov/study/NCT04574583,COMPLETED,Metastatic Cancer|Solid Tumors,DRUG: SX-682|DRUG: M7824|BIOLOGICAL: MVA-BN-CV301|BIOLOGICAL: recombinant fowlpox viral (FPV)-CV301,National Cancer Institute (NCI),,INTERVENTIONAL,,Both,Yes,3+3,,No,12,5,,Yes,12,Yes,,Yes,12,Same as dose-expansion,,,,,
NCT03332498,"Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers",https://clinicaltrials.gov/study/NCT03332498,COMPLETED,Colon Cancer|Colorectal Cancer|Colorectal Carcinoma|Colon Disease,DRUG: Pembrolizumab|DRUG: Ibrutinib,H. Lee Moffitt Cancer Center and Research Institute,"Janssen Scientific Affairs, LLC|Merck Sharp & Dohme LLC",INTERVENTIONAL,,Combination,Yes,3+3,,No,40,,,No,,,,Yes,40,total enrollment N=40,,,,,
NCT03745989,Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014),https://clinicaltrials.gov/study/NCT03745989,COMPLETED,Solid Tumors,DRUG: MK-8353|DRUG: Selumetinib,Merck Sharp & Dohme LLC,,INTERVENTIONAL,,Combination,Yes,mTPI,,Yes,30,5,,No,,,,No,,,,,,,
NCT03508726,High Dose Ascorbate With Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas,https://clinicaltrials.gov/study/NCT03508726,COMPLETED,Soft Tissue Sarcoma,DRUG: Ascorbate,Mohammed Milhem,University of Iowa,INTERVENTIONAL,,Single ,Yes,,,No,25,2,,No,,,,Yes,25,total enrollment N=25,,,,,
NCT04122625,Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143,https://clinicaltrials.gov/study/NCT04122625,COMPLETED,Solid Tumor,DRUG: Debio 1143|DRUG: Nivolumab,Debiopharm International SA,,INTERVENTIONAL,,Combination,Yes,3+3,,No,46,2,,No,,,,Yes,46,total enrollment N=46,,,,,
NCT03840200,"A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.",https://clinicaltrials.gov/study/NCT03840200,COMPLETED,Breast Cancer|Prostate Cancer|Ovarian Cancer,DRUG: Ipatasertib|DRUG: Rucaparib,Hoffmann-La Roche,,INTERVENTIONAL,,Combination,Yes,,,Yes,51,3,,Yes,51,No,,No,,,,,,,
NCT03481816,Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines,https://clinicaltrials.gov/study/NCT03481816,COMPLETED,Prostatic Neoplasms|Prostatic Cancer,BIOLOGICAL: ETBX-071; adenoviral PSA vaccine|BIOLOGICAL: ETBX-061; adenoviral MUC1 vaccine|BIOLOGICAL: ETBX-051; adenoviral brachyury vaccine,National Cancer Institute (NCI),,INTERVENTIONAL,,Combination,Yes,,,,18,3,,Yes,18,No,,No,,,,,,,
NCT03340974,Pilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer,https://clinicaltrials.gov/study/NCT03340974,COMPLETED,Pancreatic Cancer|Stereotactic Body Radiation Therapy,DRUG: GC4419|DRUG: Placebo|RADIATION: Stereotactic Radiation Therapy (SBRT) 50 Gy|RADIATION: Stereotactic Radiation Therapy (SBRT) 55 Gy,"Galera Therapeutics, Inc.",M.D. Anderson Cancer Center,INTERVENTIONAL,,Combination,Yes,Other,Parallel Assignment,Yes,42,3,,No,,,,Yes,42,total enrollment N=42,,,,,
NCT03711604,Compassionate Use Study of Tenalisib (RP6530),https://clinicaltrials.gov/study/NCT03711604,COMPLETED,Hematological Malignancies,DRUG: Tenalisib,Rhizen Pharmaceuticals SA,,INTERVENTIONAL,,Both,Yes,,,No,,,,No,,,,Yes,17,total enrollment N=17,,,,,
NCT04034238,"Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors",https://clinicaltrials.gov/study/NCT04034238,COMPLETED,"Neoplasms With Mesothelin Expression|Epithelioid Mesothelioma|Cholangiocarcinoma, Extrahepatic|Adenocarcinoma, Pancreatic",DRUG: LMB-100|DRUG: Tofacitinib|DEVICE: Mesothelin Expression,National Cancer Institute (NCI),,INTERVENTIONAL,,Combination,Yes,3+3,,No,19,2,,Yes,19,No,,No,,,,,,,
NCT04538950,PET/CT Quantitative Assessment of Myocardial Blood Flow Changes in Oncologic Patients Receiving Checkpoint Inhibitor Therapy,https://clinicaltrials.gov/study/NCT04538950,COMPLETED,Cancer,DIAGNOSTIC_TEST: PET/CT|DRUG: radioactive drug (tracer),Mayo Clinic,,INTERVENTIONAL,,Single ,No,,,,,,,No,,,,Yes,6,,,,,,
NCT03733210,Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer,https://clinicaltrials.gov/study/NCT03733210,COMPLETED,Squamous Cell Carcinoma of the Head and Neck|Carcinoma of the Head and Neck,DRUG: Panitumumab-IRDye800|DRUG: 89-Zirconium (Zr-89) Panitumumab|DEVICE: Pinpoint IR IR9000 fluorescence imaging system (FIS)|DEVICE: SPY-PHI IR9000 fluorescence imaging system (FIS)|DEVICE: Explorer Air camera|DEVICE: PDE-NEO II camera|DEVICE: FIS-00 fluorescence imaging system (FIS)|DEVICE: Da Vinci Firefly Imaging System|DEVICE: IGP-ELVIS-v4 Macroscopic Specimen Imager|DEVICE: Vevo 3100 LAZR-X|DEVICE: Pearl Triology Imaging System|DEVICE: Odyssey CLx Imaging System|DEVICE: Leica fluorescence microscope,Andrei Iagaru,National Institutes of Health (NIH)|National Cancer Institute (NCI),INTERVENTIONAL,,Combination,No,,,,,,,No,,,,No,,,,,,,
NCT03340766,Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL),https://clinicaltrials.gov/study/NCT03340766,COMPLETED,Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL),DRUG: Blinatumomab|DRUG: Pembrolizumab,Amgen,Merck Sharp & Dohme LLC,INTERVENTIONAL,,Combination,Yes,Other,Sequential Assignment,No,31,3,,Yes,,No,,No,,,,,,,
NCT03831711,68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer,https://clinicaltrials.gov/study/NCT03831711,COMPLETED,Breast Carcinoma|Estrogen Receptor Positive,DRUG: Gallium Ga 68-labeled GRPR Antagonist BAY86-7548|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Positron Emission Tomography|DEVICE: Investigational software and coils in PET/MR scan,Andrei Iagaru,General Electric,INTERVENTIONAL,,Single ,No,,,,93,,,No,,,,No,,,,,,,
NCT03684811,A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation,https://clinicaltrials.gov/study/NCT03684811,COMPLETED,"Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme)|Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas)|Cohort 3a and 3b: Chondrosarcoma|Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma|Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations",DRUG: FT-2102|DRUG: Azacitidine|BIOLOGICAL: Nivolumab|DRUG: Gemcitabine and Cisplatin,"Forma Therapeutics, Inc.",,INTERVENTIONAL,,Combination,Yes,3+3,,No,8,2,,Yes,93,No,,Yes,93,total enrollment N=93,,,,,
NCT03309878,Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma,https://clinicaltrials.gov/study/NCT03309878,COMPLETED,Recurrent Diffuse Large B-Cell Lymphoma|Recurrent High Grade B-Cell Lymphoma|Recurrent Transformed B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory High Grade B-Cell Lymphoma|Refractory Transformed B-Cell Non-Hodgkin Lymphoma,BIOLOGICAL: Mogamulizumab|BIOLOGICAL: Pembrolizumab,National Cancer Institute (NCI),,INTERVENTIONAL,,Combination,Yes,3+3,,No,,1,,,,No,,Yes,8,total enrollment N=8,,,,,
NCT03822871,A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer,https://clinicaltrials.gov/study/NCT03822871,COMPLETED,Prostate Cancer,DRUG: CTT1403|DRUG: CTT1057|DRUG: 68Ga-PSMA-11,Cancer Targeted Technology,"University of California, San Francisco|National Cancer Institute (NCI)",INTERVENTIONAL,,Single ,Yes,3+3,,No,17,10,,Yes,17,No,,No,,,,,,,
NCT03426605,A Study of LAM-003 in Patients With Acute Myeloid Leukemia,https://clinicaltrials.gov/study/NCT03426605,COMPLETED,Oncology|Acute Myeloid Leukemia,DRUG: Open Label LAM-003,OrphAI Therapeutics,,INTERVENTIONAL,,Single ,Yes,3+3,,No,17,3,,No,,,,No,,,,,,,
NCT03987854,The University of Michigan PCOS Intervention Using Nutritional Ketosis,https://clinicaltrials.gov/study/NCT03987854,COMPLETED,Polycystic Ovary Syndrome,BEHAVIORAL: diet and lifestyle program,University of Michigan,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),INTERVENTIONAL,,None,No,,,,,,,No,,,,No,,,,,,,
NCT03813147,"Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome",https://clinicaltrials.gov/study/NCT03813147,COMPLETED,Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia|Recurrent Myelodysplastic Syndrome|Refractory Acute Myeloid Leukemia|Refractory Myelodysplastic Syndrome,DRUG: Azacitidine|DRUG: Cytarabine|DRUG: Fludarabine Phosphate|DRUG: Methotrexate|DRUG: Pevonedistat|DRUG: Therapeutic Hydrocortisone,National Cancer Institute (NCI),Children's Oncology Group,INTERVENTIONAL,,Combination,Yes,Other,Rolling 6 Design,No,12,2,,No,,,,No,,,,,,,
NCT03848845,"Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)",https://clinicaltrials.gov/study/NCT03848845,COMPLETED,Multiple Myeloma,DRUG: belantamab mafodotin|DRUG: Pembrolizumab,GlaxoSmithKline,Merck Sharp & Dohme LLC,INTERVENTIONAL,,Combination,Yes,,,No,41,2,,Yes,41,No,,Yes,41,total enrollment N=41,,,,,
NCT03532451,Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer,https://clinicaltrials.gov/study/NCT03532451,COMPLETED,Bladder Cancer,DRUG: Nivolumab|DRUG: Nivolumab/Lirilumab,"PrECOG, LLC.",Bristol-Myers Squibb,INTERVENTIONAL,,Both,No,,,,,,,Yes,43,Yes,,No,,,,,,,
NCT04147247,A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread,https://clinicaltrials.gov/study/NCT04147247,COMPLETED,Neoplasms,DRUG: BI 905681,Boehringer Ingelheim,,INTERVENTIONAL,,Single ,Yes,Other,EWOK,No,21,5,,Yes,21,Yes,,No,,,,,,,
NCT04216251,PRevention Using EPA Against coloREctal Cancer,https://clinicaltrials.gov/study/NCT04216251,COMPLETED,Colorectal Adenoma|Colorectal Cancer|Endoscopic Surgery|Eicosapentaenoic Acid|Gastrointestinal Microbiome,DRUG: AMR101,Massachusetts General Hospital,National Institutes of Health (NIH),INTERVENTIONAL,,Single ,No,,,,,,,No,,,,No,,,,,,,
NCT03323151,A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma,https://clinicaltrials.gov/study/NCT03323151,COMPLETED,Mantle-Cell Lymphoma,DRUG: Ixazomib|DRUG: Ixazomib|DRUG: Ibrutinib|DRUG: Ibrutinib,"PrECOG, LLC.",Takeda,INTERVENTIONAL,,Combination,Yes,3+3,,Yes,,3,,,,,,Yes,43,43,,,,,